Compounded Semaglutide Providers 2026: Who Still Offers It, Pricing & Safety

Compounded Semaglutide Providers 2026: Who Still Offers It, Pricing & Safety

The compounded semaglutide market is shrinking. Hims is exiting compounded GLP-1s entirely. The FDA has sent 30+ warning letters to compounding pharmacies. The SAFE Drugs Act could restrict compounding further. And the April 2-3, 2026 response deadline for warned companies will likely remove more suppliers from the market.

Despite all of this, eight major telehealth providers still offer compounded semaglutide as of April 2026. This roundup covers every one of them — pricing, safety, pharmacy sourcing, and what to watch for in the months ahead.

Important: Compounded semaglutide is not FDA-approved as a finished product. It is prepared by compounding pharmacies under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Quality, potency, and sterility vary between pharmacies. This article is informational — not a recommendation to use compounded medications over FDA-approved alternatives.

What is the compounded semaglutide landscape in April 2026?

Eight major telehealth providers still offer compounded semaglutide as of April 2026, but the market is shrinking fast: Hims has exited, the FDA has issued 30+ warning letters, and brand-name alternatives are becoming more affordable. Patients still on compounded options should have a backup plan.

Six months ago, finding compounded semaglutide was straightforward. A dozen or more telehealth platforms offered it, prices were dropping, and regulatory enforcement was limited.

That landscape has changed significantly:

• Hims is exiting compounded semaglutide. The largest telehealth platform selling compounded GLP-1s struck a deal with Novo Nordisk to transition patients to brand Wegovy. Existing patients are being migrated; new prescriptions for compounded semaglutide from Hims are no longer available.
• FDA enforcement is accelerating. Over 30 warning letters have been sent to compounding pharmacies since late 2025, citing concerns about sterility, potency accuracy, and marketing claims.
• The SAFE Drugs Act remains in play. If passed, this legislation would impose additional restrictions on how compounding pharmacies produce and distribute semaglutide and tirzepatide copies.
• Insurance coverage is expanding. Medicare's $50/month cap on GLP-1 medications (starting April 2026) and broader commercial coverage are making brand-name options cost-competitive with compounded versions for more patients.

The result: the compounded semaglutide market is consolidating. Fewer providers, more regulatory scrutiny, and growing alternatives. The eight providers below are still actively offering compounded semaglutide as of this writing.

How do compounded semaglutide providers compare on price?

SkinnyRx is the cheapest at $129/month; Henry Meds is $149/month (or $129 with loyalty). Mochi Health's $99 medication price becomes $178/month when you add the required $79 membership. For patients searching "cheapest way to get semaglutide online," SkinnyRx and Henry Meds are the current leaders.

All prices reflect April 2026 rates for compounded injectable semaglutide. Prices are flat-rate unless otherwise noted — meaning the monthly cost stays the same regardless of your dose as you titrate up.

Provider	Semaglutide/mo	Tirzepatide/mo	Consultation	Flat-rate doses?
SkinnyRx	$129	$249	Included	Yes
Henry Meds	$149 ($129 loyalty)	$349	Included	Yes
Ro	$149	N/A	Included	Yes
Nurx	$150	$250	Included	Yes
Shed	$175	$325	Included	No
Mochi Health	$99 + $79 membership = $178	$199 + $79 = $278	Included in membership	Yes
PlushCare	$189	$349	$15/mo membership	No
MEDVi	$199	$349	Included	No

How to read this table:

• Providers are sorted by effective monthly semaglutide cost (lowest to highest).
• "Flat-rate doses" means your price stays the same whether you're on 0.25 mg or 2.4 mg. Providers without flat-rate pricing may charge more at higher doses.
• Mochi Health's total cost includes a mandatory $79/month membership fee on top of the medication price. PlushCare charges a separate $15/month membership.
• Ro does not currently offer compounded tirzepatide.

Cheapest compounded semaglutide: SkinnyRx at $129/month, followed by Henry Meds at $149/month (or $129/month with their loyalty discount). If you value clinical depth over raw price, factor in what's included — see the provider-by-provider breakdown below.

Which compounded semaglutide provider should you choose?

The right provider depends on your priorities: price (SkinnyRx or Henry Meds), clinical depth (Mochi Health), platform stability (Ro or Nurx), or tirzepatide availability (most except Ro). The breakdown below covers each option in detail.

Henry Meds — $149/month ($129 loyalty)

Henry Meds is one of the most established telehealth platforms for compounded GLP-1s. They offer both compounded semaglutide and compounded tirzepatide with flat-rate dosing.

• Semaglutide: $149/month, or $129/month with a loyalty discount for returning patients
• Tirzepatide: $349/month
• Consultation: Included — async provider review
• Pharmacy model: 503B outsourcing facility partners
• Shipping: Free, typically 3-5 business days
• Clinical model: Async consultations with licensed providers. Ongoing messaging for dose adjustments.
• Notable: One of the few providers offering a loyalty discount that meaningfully reduces the monthly price. Long operational track record in compounded peptides.

Best for: Patients who want a reliable, mid-price option with a track record and flat-rate dosing.

Ro — $149/month

Ro (formerly Roman/Rory) is a large, well-funded telehealth platform. They offer compounded semaglutide but not compounded tirzepatide.

• Semaglutide: $149/month
• Tirzepatide: Not available
• Consultation: Included — async provider review
• Pharmacy model: 503B outsourcing facility partners
• Shipping: Free
• Clinical model: Async consultations. Provider messaging available for adjustments.
• Notable: Backed by significant venture capital. Strong operational infrastructure. However, the lack of a tirzepatide option limits flexibility if your provider recommends switching medications.

Best for: Patients who want semaglutide specifically and value a well-established platform. Not ideal if you might want tirzepatide later.

SkinnyRx — $129/month

SkinnyRx offers the lowest headline price for compounded semaglutide among the providers in this roundup.

• Semaglutide: $129/month
• Tirzepatide: $249/month
• Consultation: Included
• Pharmacy model: 503B outsourcing facility partners
• Shipping: Free
• Clinical model: Async consultations with licensed providers.
• Notable: Lowest price for both compounded semaglutide and compounded tirzepatide. Newer platform with less public track record than Henry Meds or Ro.

Best for: Price-conscious patients who want the lowest monthly cost and are comfortable with a newer provider.

Mochi Health — $178/month effective

Mochi Health operates on a membership model that separates the medication cost from platform access. The total effective cost is higher than the medication price alone.

• Semaglutide: $99/month medication + $79/month membership = $178/month effective
• Tirzepatide: $199/month medication + $79/month membership = $278/month effective
• Consultation: Video consultations with obesity medicine specialists included in membership
• Pharmacy model: 503B outsourcing facility partners
• Shipping: Free
• Clinical model: Video consultations (not just async) with board-certified obesity medicine providers. Registered dietitian access included in membership.
• Notable: The most clinically comprehensive option in this roundup. Video visits with specialists, dietitian support, and insurance navigation assistance are all included. The membership model means you're paying more than the $99 headline price suggests, but you're also getting significantly more clinical support.

Best for: Patients who want clinical guidance alongside their prescription — obesity medicine specialists, dietitian access, and structured follow-up. The $178/month effective cost is justified if you'll use the clinical support.

Nurx — $150/month

Nurx is part of the Thirty Madison family of telehealth brands. They offer both compounded semaglutide and tirzepatide at competitive prices.

• Semaglutide: $150/month
• Tirzepatide: $250/month
• Consultation: Included
• Pharmacy model: 503B outsourcing facility partners
• Shipping: Free
• Clinical model: Async consultations with licensed providers. Messaging available.
• Notable: Part of a larger telehealth conglomerate, which provides institutional stability. Competitive pricing on both medications.

Best for: Patients who want mid-range pricing with the backing of an established telehealth company.

PlushCare — $189/month + $15 membership

PlushCare is primarily a primary care telehealth platform that also offers weight management. Their pricing includes a separate membership fee, and doses are not flat-rate.

• Semaglutide: $189/month + $15/month membership = $204/month effective
• Tirzepatide: $349/month + $15/month membership = $364/month effective
• Consultation: Video consultations included with membership
• Pharmacy model: Partners with compounding pharmacies
• Shipping: Included
• Clinical model: Video consultations with licensed providers (not obesity medicine specialists specifically).
• Notable: PlushCare offers broader primary care services, so patients already using the platform for other healthcare needs can add weight management. However, doses are not flat-rate — costs may increase as you titrate to higher doses. The $15/month membership adds to the effective cost.

Best for: Existing PlushCare patients who want to consolidate their telehealth care. Less ideal as a standalone weight loss platform given the higher effective price and lack of flat-rate dosing.

Shed — $175/month

Shed is a weight-loss-focused telehealth platform offering compounded semaglutide and tirzepatide without flat-rate dosing.

• Semaglutide: $175/month
• Tirzepatide: $325/month
• Consultation: Included
• Pharmacy model: Compounding pharmacy partners
• Shipping: Included
• Clinical model: Provider consultations with ongoing support.
• Notable: Mid-range pricing, but the lack of flat-rate dosing means your costs could increase at higher doses. Less established than platforms like Ro or Henry Meds.

Best for: Patients seeking a mid-tier option who expect to stay at lower doses.

MEDVi — $199/month

MEDVi offers compounded semaglutide and tirzepatide at the higher end of the pricing spectrum in this roundup, without flat-rate dosing.

• Semaglutide: $199/month
• Tirzepatide: $349/month
• Consultation: Included
• Pharmacy model: Compounding pharmacy partners
• Shipping: Included
• Clinical model: Provider consultations with follow-up support.
• Notable: Higher pricing without flat-rate dosing. MEDVi positions itself as a clinical weight management platform, but the pricing makes it less competitive for patients whose primary concern is cost.

Best for: Patients who value MEDVi's specific clinical approach and are less price-sensitive.

What are the safety and regulatory risks of compounded semaglutide?

Compounded semaglutide is legal but carries real risks: potency can vary, sterility is not guaranteed, and some pharmacies use semaglutide salt forms not studied in clinical trials. The safest versions come from 503B outsourcing facilities that publish third-party certificates of analysis.

Compounded semaglutide occupies a legally permitted but less regulated space compared to FDA-approved medications like Wegovy. Here's what patients should understand:

What "compounded" actually means

Compounded semaglutide is prepared by a compounding pharmacy using semaglutide base (the active ingredient) combined with other ingredients to create an injectable solution. This is different from FDA-approved Wegovy, which is manufactured by Novo Nordisk under strict FDA oversight with validated potency, sterility, and stability.

Compounding is legal under two FDA pathways:

• 503A pharmacies compound medications based on individual patient prescriptions. These face less FDA oversight.
• 503B outsourcing facilities can compound medications in larger batches without individual prescriptions. They face more FDA scrutiny, including regular inspections.

The safety reality

• Potency can vary. Testing by independent labs has found some compounded semaglutide products contain more or less active ingredient than labeled. This can result in under-dosing (less effective) or over-dosing (increased side effects).
• Sterility is not guaranteed. FDA warning letters have cited sterility failures at multiple compounding pharmacies. Injectable medications with sterility issues can cause serious infections.
• No long-term stability data. Compounded formulations have not undergone the stability testing that FDA-approved products require. How the medication performs after weeks in your refrigerator is less certain.
• "Semaglutide salt" formulations. Some compounding pharmacies use semaglutide sodium or semaglutide acetate rather than the semaglutide base used in Wegovy. These salt forms have not been studied in clinical trials, and their bioequivalence to the base form is not established.

What patients should verify

Before using any compounded semaglutide provider, ask or check:

1. Is the pharmacy a 503B outsourcing facility? 503B facilities face more regulatory oversight than 503A pharmacies.
2. Is the pharmacy registered with the FDA? You can check at FDA's registered facility database.
3. Does the pharmacy provide certificates of analysis (COAs)? A COA from a third-party lab confirms potency and sterility for each batch.
4. What form of semaglutide is used? Semaglutide base is closest to what's in Wegovy. Salt forms (sodium, acetate) are less studied.

What does the Hims exit from compounded semaglutide mean for patients?

Hims' decision to exit compounded GLP-1s in favor of a Novo Nordisk brand deal is the clearest signal that the regulatory environment has become too risky for even well-funded platforms. Smaller providers still in the compounded market are working with less margin for error.

Hims was the largest telehealth platform offering compounded semaglutide, reaching millions of patients through aggressive marketing and competitive pricing. Their decision to exit compounded GLP-1s — through a deal with Novo Nordisk to transition patients to brand Wegovy — is the most significant market shift in 2026.

What happened: Hims negotiated directly with Novo Nordisk for discounted Wegovy access, choosing brand stability over the regulatory risk of continued compounding. Current compounded semaglutide patients are being transitioned to Wegovy at negotiated pricing.

What it means for patients on other platforms:

• Validation of regulatory risk. Hims had the resources to fight FDA enforcement if they chose to. That they chose to exit instead signals that even well-funded companies view the regulatory environment as increasingly hostile to compounding.
• Possible supply chain effects. Hims' compounding pharmacy partners will lose a major customer. Some may scale back production or close, which could affect supply for other telehealth platforms.
• Pricing pressure. As the largest buyer exits, smaller platforms may face higher per-unit costs from compounding pharmacies, potentially leading to price increases.
• An alternative path. Patients on compounded semaglutide who are uncomfortable with regulatory uncertainty should note that Hims' Wegovy deal may signal future arrangements between other telehealth platforms and brand manufacturers.

What is the FDA enforcement timeline for compounded semaglutide?

The April 2-3, 2026 response deadline is the most immediate pressure point — pharmacies that don't respond satisfactorily face potential enforcement action, which could disrupt supply for patients on affected platforms.

Understanding the regulatory timeline helps patients plan for potential disruption:

Date	Event	Impact
Late 2025	FDA sends 30+ warning letters to compounding pharmacies	Pharmacies given 15 business days to respond
Early 2026	Multiple pharmacies cease compounding semaglutide	Supply disruptions for some telehealth platforms
April 2026	Hims announces exit from compounded GLP-1s	Largest provider transitions to brand
April 2-3, 2026	Response deadline for warned companies	Pharmacies that don't respond satisfactorily face potential enforcement action
April 2026	Medicare $50/month GLP-1 cap takes effect	Brand medications become affordable for Medicare patients
2026 (ongoing)	SAFE Drugs Act congressional activity	If passed, could further restrict compounding of GLP-1 medications

What to watch: The April deadline is the most immediate concern. If FDA takes enforcement action against pharmacies that fail to respond adequately, patients on affected platforms could face sudden supply disruptions. Ask your provider which pharmacy compounds their medications and whether that pharmacy has received a warning letter.

When should you stay on compounded semaglutide vs. switch to brand?

Switch to brand if you're on Medicare (the $50/month cap makes brand dramatically cheaper), if your insurance now covers GLP-1s, or if you're uncomfortable with supply disruption risk. Stay compounded if you're uninsured and can't afford $1,000+/month for brand medications.

The decision isn't compounded-or-nothing anymore. Here's a framework:

Consider switching to brand Wegovy or Zepbound if:

• Your insurance now covers it. Run a benefits check. Many commercial plans that rejected GLP-1 coverage in 2024-2025 have added it. Your copay might be lower than compounded pricing.
• You're on Medicare. Starting April 2026, Medicare's $50/month cap on GLP-1s makes brand Wegovy dramatically cheaper than any compounded option. If you qualify, switch.
• You're concerned about supply disruption. FDA enforcement is real and accelerating. Brand medications don't face supply disruption from regulatory action against compounding pharmacies.
• You want oral semaglutide. Brand oral Wegovy is FDA-approved. Compounded oral semaglutide is available from very few providers and has less established dosing data.
• You want long-term certainty. If you plan to be on semaglutide for years, brand medications provide more stability than a market facing increasing regulatory pressure.

Staying compounded may still make sense if:

• You're uninsured or underinsured and brand medications cost $1,000+/month out of pocket. At $129-199/month, compounded semaglutide remains dramatically cheaper.
• Your insurance doesn't cover GLP-1s. Many plans still exclude them. Until your coverage changes, compounded is the affordable path.
• You're on compounded tirzepatide. Brand Zepbound is harder to access and more expensive out-of-pocket than brand Wegovy. Compounded tirzepatide at $249-349/month may still be your best option.
• You're stable on your current dose and provider. If your compounding pharmacy is a 503B facility in good standing with the FDA, and you're responding well to treatment, there's no urgent reason to switch. But have a backup plan.

The hybrid approach

Some patients are using compounded semaglutide while simultaneously pursuing insurance approval for brand medications. This makes sense if:

• Your provider offers prior authorization support (Mochi Health does; most others don't)
• You're willing to transition when/if coverage comes through
• You want to start treatment now rather than wait weeks or months for insurance approval

How do you evaluate a compounding pharmacy's safety?

The key signals: 503B registration (not just 503A), published third-party certificates of analysis, no active FDA warning letters, and use of semaglutide base (not sodium or acetate salt forms). If your provider won't disclose the pharmacy name, treat that as a red flag.

Not all compounding pharmacies are equal. If your telehealth provider doesn't disclose their pharmacy partner, that itself is a concern. Here's what to look for:

Green flags

• 503B outsourcing facility registration. More FDA oversight, regular inspections, and batch testing requirements.
• Published certificates of analysis (COAs). Third-party lab testing confirming potency and sterility for each batch.
• FDA-registered. Verifiable in the FDA's registered facility database.
• No FDA warning letters. Check the FDA warning letter database for your pharmacy's name.
• Uses semaglutide base (not sodium or acetate salt forms).
• cGMP-compliant facilities. Current Good Manufacturing Practice compliance indicates higher quality standards.

Red flags

• Won't disclose the pharmacy name. Transparency is baseline.
• 503A-only pharmacy compounding in large batches. 503A pharmacies should be compounding for individual prescriptions, not mass-producing.
• No third-party potency testing. Self-reported quality is not quality assurance.
• Active FDA warning letter. Check before you fill.
• Unusually low pricing. If one provider is dramatically cheaper than all others, ask why. Cutting corners on ingredients, testing, or sterility controls is how costs come down.

Frequently Asked Questions

Is compounded semaglutide the same as Wegovy?

No. Compounded semaglutide contains the same active ingredient (semaglutide) but is not manufactured by Novo Nordisk and has not undergone FDA approval as a finished product. Differences in formulation, potency accuracy, and sterility controls mean compounded versions are not identical to Wegovy, even if the active ingredient is the same.

Is compounded semaglutide legal?

Yes, as of April 2026. Compounding pharmacies operating under FDA sections 503A and 503B can legally prepare semaglutide. However, the regulatory environment is tightening, and the SAFE Drugs Act could change this if passed.

What happens if my compounding pharmacy gets shut down?

Your telehealth provider would need to find a new pharmacy partner or stop offering the medication. In practice, this could mean a gap in your supply. Patients should keep at least one month's supply on hand and know their provider's contingency plan.

Can I switch from compounded semaglutide to Wegovy mid-treatment?

Yes. Your prescribing provider can transition you to brand Wegovy. You'll typically stay at the same dose or equivalent. The transition is straightforward medically — the complexity is usually on the insurance and cost side.

Which provider should I choose?

It depends on your priorities:

• Lowest price: SkinnyRx ($129/month) or Henry Meds ($129/month with loyalty)
• Most clinical support: Mochi Health ($178/month with specialist video visits and dietitian)
• Most established platform: Ro ($149/month) or Nurx ($150/month)
• Tirzepatide option at best price: SkinnyRx ($249/month) or Nurx ($250/month)

Will compounded semaglutide still be available in 6 months?

Likely yes, but from fewer providers and possibly at higher prices. FDA enforcement, the SAFE Drugs Act, and the Hims exit are all reducing market supply. Patients who rely on compounded semaglutide should monitor regulatory developments and have a backup plan.

Related Resources

• Compounded Semaglutide vs. Brand Wegovy — Detailed comparison of compounded vs. brand
• Henry Meds vs Hims GLP-1 Comparison — Head-to-head comparison
• Ro vs Hims vs Henry Meds — Three-way comparison
• Best GLP-1 Weight Loss Programs 2026 — All providers ranked
• GLP-1 Pricing Breakdown by Provider — Complete cost comparison
• FDA Compounded GLP-1 Tracker — Live enforcement tracker